Alvotech (ALVO) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $1.78B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | IS | CEO | Lisa Graver |
| IPO Date | 2022-06-16 | CAGR | 62.44% |
| Employees | 1,279 | Website | www.alvotech.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $2.89B | P/E | -15.44 | Forward P/E | 17.82 | PEG | — |
| P/S | 3.58 | P/B | -9.69 | P/CF | -9.34 | P/FCF | -5.85 |
| Sales | $491.95M | Sales 1Y | -12.17% | Sales 3Y | 678.51% | Sales 5Y | 1279.41% |
| EPS | $-0.34 | EPS 1Y | -435.08% | EPS 3Y | -59.17% | EPS 5Y | -86.62% |
| Sales QoQ | -0.09% | EPS QoQ | -6229.03% | Sales QoQ Avg | -6.17% | EPS QoQ Avg | -1018.97% |
| Gross Margin | 60.45% | Operating Margin | 9.62% | Profit Margin | -36.51% | ROCE | 3.77% |
| ROA | -11% | ROE | 77% | Altman Z Score | -1.21 | Piotroski Score | — |
| Current Ratio | 1.65 | Quick Ratio | 0.96 | Cash Ratio | 0.43 | Op. CF Ratio | -0.06 |
| Debt/Equity | -7.58 | Debt/Assets | 0.91 | Lt Debt/Equity | -7.3 | Lt Debt/Cap. | 1.18 |
| Intrst Cov. | 0.3 | Inventory Turnover | 0.86 | Asset Turnover | 0.31 | Receivables Turnover | 4.26 |
| Enterprise Value | $2.89B | P/E Ratio | -15.44 |
| Forward P/E | 17.82 | PEG Ratio | — |
| P/S Ratio | 3.58 | P/B Ratio | -9.69 |
| P/CF Ratio | -9.34 | P/FCF Ratio | -5.85 |
| EPS | $-0.34 | EPS Growth 1Y | -435.08% |
| EPS Growth 3Y | -59.17% | EPS Growth 5Y | -86.62% |
| Revenue Growth 1Y | -12.17% | Gross Margin | 0.6% |
| Operating Margin | 0.1% | Profit Margin | -0.37% |
| ROE | 0.77% | ROA | -0.11% |
| ROCE | 0.04% | Current Ratio | 1.65 |
| Quick Ratio | 0.96 | Cash Ratio | 0.43 |
| Debt/Equity | -7.58 | Interest Coverage | 0.3 |
| Altman Z Score | -1.21 | Piotroski Score | — |
Alvotech (ALVO) valuation & financials
Alvotech (ALVO) has a market capitalization of $1.78B and trades at a price-to-earnings ratio of -15.4. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Alvotech's revenue grew -12.2% over the last year.
Alvotech's next earnings report is scheduled for November 11, 2026 after market close; analysts estimate EPS of $-0.04. Check the earnings calendar to see all companies reporting this week.
Alvotech (ALVO) — frequently asked questions
When does Alvotech (ALVO) report earnings next?
Alvotech is expected to report earnings on November 11, 2026 after market close. Analysts estimate EPS of $-0.04.
What is Alvotech's market cap?
Alvotech (ALVO) has a market capitalization of $1.78B.
What is ALVO's P/E ratio?
Alvotech trades at a price-to-earnings ratio of -15.4, with trailing twelve-month EPS of $-0.34.
How fast is Alvotech growing?
Alvotech's revenue grew -12.2% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)